A diabetes drug has been approved to treat obesity in children and adolescents.
This was after a study showed positive effects on BMI.

The US FDA has approved the drug Wegovy (semaglutide) treat obesity in children as young as 12 years .
It works by suppressing appetite, which then reduces caloric intake and leads to weight loss.
While treatment with diabetes drugs for ailments like PCOS is common and metformin is generally prescribed in PCOS related obesity, with Wegoy it is a step further making it a promising option to treat obesity in adolescents and children. The U.S. Food and Drug Administration has approved the diabetes drug Wegovy (semaglutide) to treat obesity in teens, according to Novo Nordisk, which makes Wegovy.
This is a good news as childhood obesity has become a major concern across the world.
The news comes weeks after a study found that the obesity and type 2 diabetes drug semaglutide is just as effective in adolescents with obesity as it is in adults with obesity.

The drug is injected once a week and is used under the brand names of Ozempic and Wegovy.

Approval comes after major study
The study, which was published in The New England Journal of Medicine in December, found that adolescents with obesity who took the drug and practiced lifestyle interventions experienced a 16% reduction in body mass index (BMI) within 68 weeks.

The drug also led to improvements in cardiometabolic health issues.

Semaglutide, a glucagon-like peptide-1 analogue, is currently only approved for adults with obesity or obesity-related health conditions. It works by suppressing appetite, which then reduces caloric intake and leads to weight loss.


Source -health line
Read the full article here

https://www.healthline.com/health-news/fda-approves-diabetes-drug-semaglutide-wegovy-for-weight-loss-teens